Renin Inhibitors

  • R. Henning
  • A. Wagner
  • B. A. Schölkens
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 93 / 1)


The very high utility of inhibitors of angiotensin converting enzyme (ACE) for the amelioration of all forms of hypertension has made them drugs of choice for basic treatment. Many researchers have now focussed their interest on renin inhibitors with the hope that interference with the renin-angiotensin system at the level of this highly specific enzyme will give rise to antihypertensive agents with a low incidence of side effects.


Angiotensin Converting Enzyme Aspartic Proteinase Renin Inhibitor Renin Gene Human Renin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akahane K, Nakagawa S, Umeyama H (1985a) Three-dimensional structure of human renin and renin inhibitors. New approach to drug design. J Pharmacobiodyn 8: S174Google Scholar
  2. Akahane K, Umeyama H, Nakagawa S, Moriguchi I, Hirose S, Iizuka K, Murakami K (1985b) Three-dimensional structure of human renin. Hypertension 7: 3–12PubMedGoogle Scholar
  3. Andreeva NS, Zdanov AS, Gustchina AE, Fedorov AA (1984) Structure of ethanolinhibited porcine pepsin at 2-Â resolution and binding of the methyl ester of phenylalanyl-diiodotyrosin to the enzyme. J Biol Chem 259: 11353–11365PubMedGoogle Scholar
  4. Antonaccio MJ, Cushman DW (1981) Drugs inhibiting the renin-angiotensin system. Fed Proc 40: 2275–2284PubMedGoogle Scholar
  5. Antonaccio MJ, Wright JJ (1987) Enzyme inhibitors of the renin-angiotensin system. Prog Drug Res 31: 161–191PubMedGoogle Scholar
  6. Arrowsmith R, Carter K, Dann JG, Davies DE, Harris J, Morton JA, Lister P, et al. (1986) Novel renin inhibitors: synthesis of aminostatine and comparison with statine-containing analogues. J Chem Commun:755–757Google Scholar
  7. Blaine EH, Schorn TW, Boger J (1984) Statine-containing renin inhibitor. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. Hypertension [Suppl 1] 6: 111–118Google Scholar
  8. Blaine EH, Nelson BJ, Seymour AA, Schorn TW, Sweet CS, Slater EE, Nussberger J, Boger J (1985) Comparison of renin and converting enzyme inhibition in sodiumdeficient dogs. Hypertension [Suppl 1] 7: 166–171Google Scholar
  9. Blundell T, Sibanda BL, Pearl L (1983) Three-dimensional structure, specificity and catalytic mechanism of renin. Nature 304: 273–275PubMedCrossRefGoogle Scholar
  10. Blundell TL, Cooper J, Foundling SI, Jones DM, Atrash B, Szelke M (1987) On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. Biochemistry 26: 5585–5590PubMedCrossRefGoogle Scholar
  11. Bock MG, DiPardo RM, Evans BE, Rittle KE, Boger JS, Freidinger RM, Veber DF (1985) Dipeptide analogues. Synthesis of a potent renin inhibitor. J Chem Soc Chem Commun 109–110Google Scholar
  12. Bock MG, DiPardo RM, Evans BF, Rittle KE, Boger J, Poe M, LaMont BI, et al. (1987) Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini. J Med Chem 30: 1853–1857PubMedCrossRefGoogle Scholar
  13. Boger J (1985a) Renin inhibitors. Design of angiotensin transition-state analogs containing statine. In: Kostka V (ed) Aspartic proteinases and their inhibitors. Springer, Berlin Heidelberg New York, pp 401–420Google Scholar
  14. Boger J (1985b) Renin inhibition. Annu Rep Med Chem 20: 257–266CrossRefGoogle Scholar
  15. Boger J (1986) Renin inhibitors: Drug design and molecular modelling. In: Lambert BW (ed) Third SCI-RSC medicinal chemistry symposium, Cambridge, Sept 15–18. Royal Society of chemistry, London, pp 271–292Google Scholar
  16. Boger J (1987) Clinical goal in sight for small molecule renin inhibitors. Trends Pharm Sci 8: 370–372CrossRefGoogle Scholar
  17. Boger J, Lohr N, Ulm EH, Poe M, Blaine EM, Fanelli GM, Lin T-Y, et al. (1983) Novel renin inhibitors containing the amino acid statine. Nature 303: 81–84PubMedCrossRefGoogle Scholar
  18. Boger J, Payne LS, Perlow DS, Lohr NS, Poe M, Blaine EH, Ulm EH, et al. (1985a) Renin inhibitors. Synthesis of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem 28: 1779–1790PubMedCrossRefGoogle Scholar
  19. Boger J, Bennett CD, Payne LS, Ulm EH, Blaine EH, Homnick CF, Schorn TW, et al. (1985b) Design of proteolytically-stable, peptidal renin inhibitors and determination of their fate in vivo. Regul Pept 11: 8–13CrossRefGoogle Scholar
  20. Bolis G, Fung AKL, Greer J, Kleinert HD, Marcotte PA, Perun TJ, Plattner JJ, Stein HH (1987) Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond. J Med Chem 30: 1729–1737Google Scholar
  21. Bott R, Subramanian E, Davies DR (1982) Three-dimensional structure of the complex of the Rhizopus chinensis carboxyl proteinase and pepstatin at 2.5 A resolution. Biochemistry 21: 6956–6962PubMedCrossRefGoogle Scholar
  22. Breipohl G, Geiger R, Henke S, Kleemann H-W, Knolle J, Ruppert D, Scholkens BA, et al. (1987) Studies on renin inhibitors. Top Med Chem 4: 101–127Google Scholar
  23. Brunner HR, Nussberger J, Waeber B (1988) ACE inhibition and renin inhibition. Symposium: Renin inhibitors-present and future, Osaka, May 28Google Scholar
  24. Bühlmayer P, Caselli A, Fuhrer W, Goschke R, Rasetti V, Rüeger H, Stanton JL, et al. (1988) Synthesis and biological activity of some transition-state inhibitors of human renin. J Med Chem 31: 1839–1846PubMedCrossRefGoogle Scholar
  25. Burton J, Cody RJ Jr, Herd A, Haber E (1980) Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA 77: 5476–5479PubMedCrossRefGoogle Scholar
  26. Burton J, Slater EE, Corvol P, Ménard J, Hartley LH (1982a) Use of anti-human renin antisera to inhibit renin in primates. Clin Exp Hypertens [A], 4: 322–324Google Scholar
  27. Burton J, Cody R Jr, Poulsen K, Hartley LH, Slater EE, Haber E (1982b) The design of specific inhibitors of renin which are active in vivo. In: Yashida Y, Hagihara Y, Ebashi S (eds) Advances in pharmacology and therapeutics, vol 2. Pergamon, London, pp 231–241Google Scholar
  28. Burton J, Hyun H, TenBrink RE (1983) The design of substrate analog renin inhibitors. In: Hruby VB, Rich DH (eds) Peptides: structure and function. Pierce, Rockford, IL, pp 559–567Google Scholar
  29. Campbell DJ (1985) The site of angiotensin production. J Hypertens 3: 199–207PubMedCrossRefGoogle Scholar
  30. Campbell DJ (1987) Circulating and tissue angiotensin systems. J Clin Invest 79: 1–6PubMedCrossRefGoogle Scholar
  31. Carlson W, Handschumacher M, Haber E (1984) Studies of the three-dimensional structure of human renin and its inhibitors. J Hypertens [Suppl 3] 2: S281–S284Google Scholar
  32. Carlson W, Karplus M, Haber E (1985) Construction of a model for the threedimensional structure of human renal renin. Hypertension 7: 199–207Google Scholar
  33. Carlson WD, Handschumacher M, Summers M, et al. (1987) Models for the threedimensional structure of renin inhibitors bound in the active site of human renin: an analysis of the properties that produce tight binding. J Cardiovasc Pharmacol [Suppl 7] 10: S91–S93CrossRefGoogle Scholar
  34. Cody RJ, Burton J, Evin G, Poulsen K, Herd JA, Haber E (1980) A substrate analog inhibitor of renin that is effective in vivo. Biochem Biophys Res Commun 97: 230–235PubMedCrossRefGoogle Scholar
  35. Corvol P, Menard J (1986) From the renin gene to renin inhibitors. Ann Endocrinol (Paris) 47: 156–166Google Scholar
  36. Corvol P, Michel JB, Evin G, et al. (1983) Inhibition of the renin system at the level of the renin-substrate reaction. Ann Endocrinol (Paris) 44: 339–342Google Scholar
  37. Cumin F, Evin G, Fehrentz J-A, Seyer R, Castro B, M6nard J, Corvol P (1985) Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem 260: 9154–9157PubMedGoogle Scholar
  38. Cumin F, Nisato D, Gagnol J-P, Corvol P (1987a) A potent radiolabeled human renin inhibitor, 3H-SR42128: Enzymatic, kinetic, and binding studies to renin and other aspartic proteases. Biochemistry 26: 7615–7621Google Scholar
  39. Cumin F, Nisato D, Gagnol J-P, Corvol P (1987b) Binding of a tritiated pepstatin analog to human renin. J Cardiovasc Pharmacol [Suppl 7] 10: S102–S104CrossRefGoogle Scholar
  40. Dann JG, Stammer DK, Harris CJ, Arrowsmith RJ, Davies DE, Hardy GW, Morton JA (1986) Human renin: A new class of inhibitors. Biochem Biophys Res Commun 134: 71–77Google Scholar
  41. De Clavtere M, Fourment P, Richaud JP, Vukovic J, Gagnol J-P, Mague G (1985a) Haemodynamic effects of the renin inhibitor SR 42128 in conscious baboons. J Hypertens [Suppl 3] 3: S271–S273Google Scholar
  42. De Clavifcre M, Cazaubon C, Lacoure C, Nisato D, Gagnol JP, Evin G, Corvol P (1985b) In vitro and in vivo inhibition of human and primate renin by a new potent renin inhibitor: SR 42128. J Cardiovasc Pharmacol [Suppl 4] 7: S58–S61CrossRefGoogle Scholar
  43. DeForrest JM, Waldron TL, Oehl RS, Scalese RJ, Free CA, Weller HN, Ryono DE (1988) Pharmacology of novel imidazole alcohol inhibitors of primate renin. Symposium: Renin Inhibitors—Present and Future, May 28, OsakaGoogle Scholar
  44. Dellaria JF, Maki RG, Bopp BA, Cohen J, Kleinert HD, Luly JR, Mevits I, et al. (1987) Optimization and in vivo evaluation of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement. J Med Chem 30: 2137–2144PubMedCrossRefGoogle Scholar
  45. Diaz, J (1987) Pepstatin analogs:promising antihypertensive compounds. Drugs Fut 12: 1133–1144Google Scholar
  46. Dzau VJ (1985) In vivo inhibition of renin by antirenin antibodies: Potential experimental and clinical applications. J Cardiovasc Pharmacol [Suppl 4] 7: S53–S57CrossRefGoogle Scholar
  47. Dzau VJ (1986) Significance of the vascular renin-angiotensin system. Hypertension 8: 553–559PubMedGoogle Scholar
  48. Dzau VJ, Kopelman RI, Barger AC, Haber E (1980) Renin-specific antibody for study of cardiovascular homeostasis. Science 207: 1091–1093PubMedCrossRefGoogle Scholar
  49. Dzau VJ, Brenner A, Wolfsohn S, Haber E (1982) Characterization of antibodies to canine renal renin. Studies of interspecies homology of renin using antibodies as probe. Hypertension 4: 341–343Google Scholar
  50. Dzau VJ, Devine D, Mudgett-Hunter M, Kopelman RI, Barger AC, Haber E (1983) Antibodies as specific renin inhibitors: Studies with polyclonal and monoclonal antibodies and Fab fragments. Clin Exp Hypertens [A] 5: 1207–1220Google Scholar
  51. Dzau VJ, Kopelman RI, Barger AC, Haber E (1984) A comparison of renin specific IgG and Fab in studies of blood pressure regulation. Am J Physiol 246: H404–H409PubMedGoogle Scholar
  52. Eid M, Evin G, Castro B, Ménard J, Corvol P (1981) New renin inhibitors homologous with pepstatin. Biochem J 197: 465–471PubMedGoogle Scholar
  53. Epps DE, Mao B, Staples DJ, Sawyer TK (1988) Structure-conformation relationships of synthetic peptide inhibitors of human renin studied by resonance energy transfer and molecular modeling. Int J Pept Protein Res 31: 22–34PubMedCrossRefGoogle Scholar
  54. Evans BE, Rittle KE, Bock MG, Bennett CD, DiPardo RM, Boger J, Poe M, et al. (1985) A uniquely potent renin inhibitor and its unanticipated plasma binding component. J Med Chem 28: 1755–1756PubMedCrossRefGoogle Scholar
  55. Fearon K, Spaltenstein A, Hopkins PB, Gelb MH (1987) Fluoroketones containing peptides as inhibitors of human renin. J Med Chem 30: 1617–1622PubMedCrossRefGoogle Scholar
  56. Fehrentz JA, Heitz A, Castro B (1986) Synthesis of aldehydic peptides inhibiting renin. Int J Pept Protein Res 26 (3): 236–241CrossRefGoogle Scholar
  57. Fix JA, Engle K, Dorter PA, Leppert PS, Selk SJ, Gardner CR, Alexander J (1986) Acylcarnitins: drug absorbtion-enhancing agents in the gastrointestinal tract. Am J Physiol 251. G332–G340PubMedGoogle Scholar
  58. Foundling SI, Cooper J, Watson FE, Cleasby A, Pearl LH, Sibanda BL, Hemmings AM, et al. (1987a) Crystallographic studies of reduced bond inhibitors complexed with an aspartic proteinase. J Cardiovasc Pharmacol [Suppl 7] 10: S59–S68CrossRefGoogle Scholar
  59. Foundling SI, Cooper J, Watson FE, Cleasby A, Peral LH, Sibanda BL, Hemmings A, et al. (1987b) High resolution X-ray analyses of renin inhibitor-aspartic proteinase complexes. Nature 327: 349–352PubMedCrossRefGoogle Scholar
  60. Free CA, Ryono DE, Samaniego SG, Neubeck R, Petrillo EW Jr (1985) Potent and selective renin inhibitors based upon substrate analogs containing an aminoalcohol function. Fed Proc 44 (5964): 1431Google Scholar
  61. Galen FX, Devaux C, Atlas S, Guyenne T, Ménard J, Corvol P, Simon D, et al. (1984) New monoclonal antibodies directed against human renin. J Clin Invest 74: 732–735CrossRefGoogle Scholar
  62. Ganten D, Unger T, Lang RE (1984) Pharmacological interferences with the reninangiotensin system. Arzneimittelforschung 34 (10B): 1391–1398PubMedGoogle Scholar
  63. Gardes J, Evin G, Castro B, Corvol P, Ménard J (1980) Synthesis and renin inhibitory properties of a new soluble pepstatin derivative. J Cardiovasc Pharmacol 2: 687–698PubMedCrossRefGoogle Scholar
  64. Greenlee WJ (1988) Renin inhibitors. Pharm Res 4: 364–373CrossRefGoogle Scholar
  65. Guégan R, Diaz J, Cazamba C, Beaumont M, Carlet C, Clément J, Demorne H, et al. (1986) Pepstatin analogues as novel renin inhibitors. J Med Chem 29: 1152–1159PubMedCrossRefGoogle Scholar
  66. Haber E, Burtonz (1979) Inhibitors of renin and their utility in physiological studies. Fed Proc 338: 2768–2773Google Scholar
  67. Haber E (1980) The fifth Volhard lecture. Specific inhibitors of renin. Clin Sci 59: 7s–19sPubMedGoogle Scholar
  68. Haber E (1983a) Peptide inhibitors of renin in cardiovascular studies. Fed Proc 42: 3155–3161PubMedGoogle Scholar
  69. Haber E (1983b) Inhibitors of renin: Present and future. Clin Exp Hypertens 5: 1193–1205CrossRefGoogle Scholar
  70. Haber E (1984a) Renin inhibitors. N Engl J Med 311: 1631–1633PubMedCrossRefGoogle Scholar
  71. Haber E (1984b) Potential tools for determing the role of renin in human essential hypertension. J Hypertens [Suppl 1] 2: 95–103Google Scholar
  72. Haber E (1984c) The first Sir George Pickering memorial lecture. Which inhibitors will give us true insight into what renin really does? J Hypertens 2: 223–230PubMedCrossRefGoogle Scholar
  73. Haber E (1985a) Defining the physiologic and pathophysiologic roles of renin: the role of specific inhibitors. Am J Kidney Dis 5: A14–A22PubMedGoogle Scholar
  74. Haber E (1985b) Will renin inhibitors influence decision-making in antihypertensive therapy? J Hypertens [Suppl 2] 3: S71–S80Google Scholar
  75. Haber E (1986) Renin inhibitors. Hypertension 8: 1093–1095PubMedGoogle Scholar
  76. Haber E, Zusman R, Burton J, Dzau VJ, Barger AC (1983) Is renin a factor in the etiology of essential hypertension? Hypertension 5: V8–V15PubMedGoogle Scholar
  77. Haber E, Hui KY, Carlson WD, Bernatowicz MS (1987) Renin inhibitors: a search for principles of design. J Cardiovasc Pharmacol [Suppl 7] 10: S54–S58CrossRefGoogle Scholar
  78. Hallett A, Jones DM, Atrash B, Szelke M, Leckie BJ, Beattie S, Dunn BM, et al. (1985) Inhibition of aspartic proteinases by transition state substrate analogs. In: Kostka V (ed) Aspartic proteinases and their inhibitors. Springer, Berlin Heidelberg New York, pp 467–478Google Scholar
  79. Hanson GJ, Baran JS, Lindberg T, Walsh GM, Papaioannou SE, Babler M, Bittner SE, et al. (1985) Dipeptide glycols: A new class of renin inhibitors. Biochem Biophys Res Commun 132: 155–161Google Scholar
  80. Hanson GJ, Baran JS, Lowrie HS, Sarussi SJ, Yang PC, Babler M, Bittner SE, et al. (1987) Enhanced potency dipeptide glycol renin inhibitors: studies in vitro and in the conscious rhesus. Biochem Biophys Res Commun 146: 959–963PubMedCrossRefGoogle Scholar
  81. Hiwada K, Kokubu T, Murakami E, Muneta S, Morisawa Y, Yabe Y, Koike H, Iijima Y (1988) A highly potent and long-acting oral inhibitor of human renin. Hypertension 11: 708–712PubMedGoogle Scholar
  82. Hofbauer KG, Wood JM (1984) Inhibition of renin: recent developments. Contrib Nephrol 43: 144–152PubMedGoogle Scholar
  83. Hofbauer KG, Wood JM (1985) Inhibition of renin, recent immunological and pharmacological advances. Trends Pharm Sci 6: 173–177CrossRefGoogle Scholar
  84. Hofbauer KG, Fuhrer W, Heusser C, Wood JM (1985) Comparison of different drug interference with the renin-angiotensin system. J Cardiovasc Pharmacol [Suppl 4] 7: S62–S68CrossRefGoogle Scholar
  85. Hui KY, Carlson WD, Bernatowicz MS, Haber E (1987) Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. J Med Chem 30: 1287–1298PubMedCrossRefGoogle Scholar
  86. Iizuka K, Kamiya T, Kubota T, Akahane K, Umeyama H, Kiso Y (1988a) New human renin inhibitors containing an unnatural amino acid, norstatine. J Med Chem 31: 701–704PubMedCrossRefGoogle Scholar
  87. Iizuka K, Kamijo T, Kubota T, Akahane K, Harada H, Shimaoka I, Umeyama H, Kiso Y (1988b) New potent renin inhibitors. In: Shiba T, Sakakibara S (eds) Peptide chemistry 1987. Protein Research Foundation, Osaka, pp 649–652Google Scholar
  88. James MNG, Sielecki AR (1983) Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. Biochemistry 24: 3701–3713CrossRefGoogle Scholar
  89. James MNG, Sielecki AN, Fujinaga M, Muir AK, Murphy MEP, Carilli CT, Shine J (1988) The molecular structure of recombinant human renin. 18th Linderstr0m-Lang Conference on Aspartic Proteinases, July 4–8, ElsinoreGoogle Scholar
  90. Johnson RL (1984) Inhibition of renin by substrate analogue inhibitors containing the oleünic amino acid 5(S)-amino-7-methyl-3(E)-octenoic Acid. J Med Chem 27: 1351–1354PubMedCrossRefGoogle Scholar
  91. Kati WM, Pals DT, Thaisrivongs S (1987) Kinetics of the inhibition of human renin by an inhibitor containing a hydroxyethylene dipeptide isostere. Biochemistry 16: 7621–7626CrossRefGoogle Scholar
  92. Kay J (1985) Structure and activity of aspartic proteinases. Aspartic proteinases and their inhibitors. Biochem Soc Trans 13: 1027–1029PubMedGoogle Scholar
  93. Kempf DJ de Lara E, Stein RH, Cohen J, Plattner JJ (1987) Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond. J Med Chem 30: 1978–1983Google Scholar
  94. Kleinert HD, Luly JR, Marcotte PA, Perun TJ, Plattner JJ, Stein H (1988a) Renin inhibitors: Improvements in the stability and biological activity of small peptides containing novel Leu-Val replacements. FEBS Lett 230: 38–42Google Scholar
  95. Kleinert HD, Martin D, Chekal MA, Kadam J, Luly JR, Plattner JJ, Perun TJ, Luther RR (1988b) Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension 11: 613–619PubMedGoogle Scholar
  96. Kokubu T, Hiwada K (1987) Human renin inhibitors. Drugs Today 23: 101–108Google Scholar
  97. Kokubu T, Hiwada K, Ito T, Ueda E, Yamamura Y, Mitoguchi T, Shigezane K (1973) Peptide inhibitors of renin-angiotensin reaction system. Biochem Pharmacol 22: 3217–3223PubMedCrossRefGoogle Scholar
  98. Kokubu T, Hiwada K, Sato Y, Iwata T, Imamura Y, Matsueda R, Yabe Y, et al. (1984) Highly potent and specific inhibitors of human renin. Biochem Biophys Res Commun 118: 929–933PubMedCrossRefGoogle Scholar
  99. Kokubu T, Hiwada K, Murakami E, Imamura Y, Matsueda R, Yabe Y, Koike H, Iijima Y (1985) Highly potent and specific inhibitors of human renin. Hypertension [Suppl 1] 7: 8–11Google Scholar
  100. Kokubu T, Hiwada K, Nague A, Murakami E, Morisawa Y, Yabe Y, Koike H, Iijima Y (1986) Statine-containing dipeptide and tripeptide inhibitors of human renin. Hypertension [Suppl 2] 8: 111–115Google Scholar
  101. Kokubu T, Hiwada K, Murakami E, et al. (1987) In vitro inhibition of human renin by statine-containing tripeptide renin inhibitor (ES-1005). J Cardiovasc Pharmacol [Suppl 7] 10: S88–R90CrossRefGoogle Scholar
  102. Kokubu T, Hiwada K, Murakami E, Muneta S, Morisawa Y, Yabe Y, Koike H, Iijima Y (1988) A highly potent and long-acting inhibitor of human renin-derivative of thiazolylalanine cyclostatine. Clin Exp Hypertens [A] 10: 512Google Scholar
  103. Leckie BJ, Szelke M, Hallett A, Hughes M, Lever AF, Mclntyre G, Merthen JJ, Tree M (1983) Peptide inhibitors of renin. Clin Exp Hypertens [A] 5: 1221–1236CrossRefGoogle Scholar
  104. Leckie BJ, Szelke M, Atrash B, Beattie SR, Hallett A, Jones DM, Mclntyre GD, et al. (1985) Human renin inhibitors. Biochem Soc Trans 13: 1029–1032PubMedGoogle Scholar
  105. Lee VHL (1986) Enzymic barriers to peptide and protein absorption and the use of penetration enhancers to modify absorption. NATO ASI Ser [A] 125: 87–104Google Scholar
  106. Liepina I, Nikiforovich GV, Paira ACM (1984) Conformational aspects of angiotensinogen analogues with renin inhibitory activity. Biochem Biophys Res Commun 122: 700–705PubMedCrossRefGoogle Scholar
  107. Luly JR, Plattner JJ, Stein H, Yi N, Soderquist J, Marcotte PA, Kleinert HD, Perun TJ (1987) Modified peptides which display potent and specific inhibition of human renin. Biochem Biophys Res Commun 143: 44–51PubMedCrossRefGoogle Scholar
  108. Luly JR, Bolis G, Ba Maung N, Soderquist J, Dellaria JF, Stein H, Cohen J, et al. (1988) New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the PI site. J Med Chem 31: 532–539PubMedCrossRefGoogle Scholar
  109. Marciniszyn J, Hartsuck JA, Tang J (1976) Mode of inhibition of acid proteases by pepstatin. J Biol Chem 251: 7088–7094PubMedGoogle Scholar
  110. Michel J-B, Wood J, Hofbauer K, Corvol P, Ménard J (1984) Blood pressure effects of renin inhibition by human renin antiserum in normotensive marmosets. Am J Physiol 246: F309–F316PubMedGoogle Scholar
  111. Morris BJ (1988) Renin gene and protein structure; sites for renin blockade. Symposium: Renin Inhibitors-Present and Future, May 28, Osaka Neisius D, Wood JM (1987) Antihypertensive effect of a renin inhibitor in marmosets with a segmental renal infarction. J Hypertens 5: 721–725Google Scholar
  112. Nisato D, Lacacer C, Roccon A, Gayvaud R, Cazaubon C, Carlet C, Plouzauc C, et al. (1987a) Discovery and pharmacological characterization of highly potent, picomolarrange, renin inhibitors. J Hypertens [Suppl 5] 5: S23–S25Google Scholar
  113. Nisato D, Wagnon J, Callet G, Mettefeu D, Assens J-L, Plouzauc C, Tonnere B, et al. (1987b) Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin. J Med Chem 30: 2287–2291Google Scholar
  114. Oldham AA, Arnstein MJA, Major JS, Crough DP (1984) In vivo comparison of the renin inhibitor H 77 with the angiotensin-converting enzyme inhibitor captopril. J Cardiovasc Pharmacol 6: 672–677PubMedCrossRefGoogle Scholar
  115. Omura S, Imamura N, Kawakita K, Yamazaki Y, Masuma R, Takahashi Y, Tamaha H, et al. (1986) Ahpatinins, new acid protease inhibitors containing 4-amino-3-hydroxy-5-phenylpentanoic acid. J Antibiot (Tokyo) 39: 1079–1085Google Scholar
  116. Ondetti MB, Cushman DW (1982) Enzymes of the renin-angiotensin system and their inhibitors. Annu Rev Biochem 51: 283–308PubMedCrossRefGoogle Scholar
  117. Pals DT, de Graaf GL, Kati WM, Lawson JA (1985) Cardiovascular effects of a renin inhibitor in relation to posture in nonhuman primates. Clin Exp Hypertens [A] 7: 105–121Google Scholar
  118. Pals DT, Thaisrivongs S, Lawson JA, Kati WM, Turner SR, de Graaf GL, Harris DW, Johnson GA (1986) An orally active inhibitor of renin. Hypertension 8: 1105–1112Google Scholar
  119. Papaioannou S, Hanson D Jr, Babler M, Yang P-C, Bittner S, Miller A, Clare M (1985a) New class of inhibitors specific for human renin. Clin Exp Hypertens [A] 7: 1243–1257CrossRefGoogle Scholar
  120. Papaioannou S, Hanson D Jr, Babler M, Yang P-C, Bittner S, Clare M (1985b) New inhibitors specific for human renin. Fed Proc 44 (6487): 1520Google Scholar
  121. Pearl L, Blundell T (1984) The active site of aspartic proteinases. FEBS Lett 174: 96–101PubMedCrossRefGoogle Scholar
  122. Plattner JJ, Creer J, Flung AKL, Stein H, Kleinert MD, Skan HL, Smital JR, Perun TJ (1986) Peptide analogues of angiotensinogen. Effect of peptide chain length on renin inhibition. Biochem Biophys Res Commun 139: 982–990Google Scholar
  123. Poulsen K, Burton J, Haber E (1973) Competitive inhibitors of renin. Biochemistry 12: 3877–3882PubMedCrossRefGoogle Scholar
  124. Rich DH (1986) Inhibitors of aspartic proteinases. In: Barrett AJ, Salvesen G (eds) Proteinase inhibitors. Elsevier, Amsterdam, pp 129–217Google Scholar
  125. Rosenberg S, Plattner JJ, Wood KJ, Skin HK, Marcotte PM, Cohen J, Perun TJ (1987) Novel renin inhibitors containing analogues of statine retro-inverted at the Ctermini: specificity at the P2 histidine site. J Med Chem 30: 1224–1228PubMedCrossRefGoogle Scholar
  126. Roy P, Delepierre M, Wagnon J, Nisato D, Roques BP (1987) Conformational analysis of pepstatin and related renin inhibitors by 400 MHz *H N.M.R. spectroscopy. Int J Pept Protein Res 30: 44–53PubMedCrossRefGoogle Scholar
  127. Samani NJ, Swales JD, Brammar WJ (1988) Expression of the renin gene in extrarenal tissues of the rat. Biochem J 253: 907–910PubMedGoogle Scholar
  128. Sawyer TK, Pals DT, Mao B, Maggiora LL, Staples DJ,, de Vaux AE, Schostarez H et al. (1988a) Structure-conformation-activity relationships of renin inhibitory peptides having P1-P1XAA(CH2NH)YAA substitutions: molecular modeling and crystallography studies. Tetrahedron 44: 661–673CrossRefGoogle Scholar
  129. Sawyer TK, Pals DT, Mao B, Staples DJ, deVaux AE, Maggiora LL, Affholter JA, et al. (1988b) Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal N(In)-For-Trp (Ftr): angiotensinogen congeners modified by Pl-P1, Phe-Phe, Sta, Lem ß(CH(OH)CH2)Val or Lem (CH2NH) Val substitutions. J Med Chem 31: 18 - 30PubMedCrossRefGoogle Scholar
  130. Scholkens BA, Jung W (1974) Renin inhibition by pepstatin in experimental hypertension. Arch Int Pharmacodyn Ther 208: 24–34PubMedGoogle Scholar
  131. Serre M, Galindo G, Marion A, et al. (1987) Hemodynamic response to SR 42128A in normal and sodium-depleted baboons. J Cardiovasc Pharmacol [Suppl 7] 10: S99–S101CrossRefGoogle Scholar
  132. Sham HL, Rempel C, Plattner JJ, Stein H, Cohen J, Perun TJ (1986) Renin inhibitors: Tripeptides incorporating 2-substituted statine analogs which display potent and specific inhibition of human renin (Abstr 8). 191th American Chemical Society Meeting, New YorkGoogle Scholar
  133. Sham HL, Stein H, Rempel CA, Cohen J, Plattner JJ (1987) Highly potent and specific inhibitors of human renin. FEBS Lett 220: 299–301PubMedCrossRefGoogle Scholar
  134. Sham HL, Bolis G, Stein HH, Fesik SW, Marcotte PA, Plattner JJ, Rempel CA, Greer J (1988) Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen. J Med Chem 31: 284–295Google Scholar
  135. Skeggs LT, Lentz KE, Kahn JR, Hochstrasser H (1968) Kinetics of the reaction of renin with nine synthetic peptide substrates. J Exp Med 128: 13–34PubMedCrossRefGoogle Scholar
  136. Smith CW, Saneii TK, Pals DT, Scahill TA, Kamdar BV, Lawson JA (1988) Synthesis and renin inhibitory activity of angiotensinogen analogues having dehydrostatine, Lem [CH2S]Val or Lem [CH2SO]Val at the PrPi’ cleavge site. J Med Chem 31: 1377–1382PubMedCrossRefGoogle Scholar
  137. Smith SG, Seymour AA, Mazack EK, Boger J, Blaine EH (1987) Comparison of a new renin inhibitor and enalaprilat in renal hypertensive dogs. Hypertension 9: 150–156PubMedGoogle Scholar
  138. Szelke M, Leckie BJ, Hallett A, Jones DM, Sueiras-Diaz J, Atrash B, Lever AF (1982) Potent new inhibitors of renin. Nature 299: 555–557PubMedCrossRefGoogle Scholar
  139. Szelke M, Jones DM, Atrash B, Hallett A, Leckie BJ (1983) Novel transition state analog inhibitors of renin. In: Hruby VJ, Rich DH (eds) Peptides: structure and function. Pierce, Rockford, IL, pp 579–582Google Scholar
  140. Szelke M, Tree M, Leckie BJ, Jones MD, Atrash B, Beattie S, Donovan B, et al. (1985) A transition-state analogue inhibitor of human renin (H 261): test in vitro and a comparison with Captopril in the anaesthetized baboon. J Hypertens 3: 13–18PubMedCrossRefGoogle Scholar
  141. Takaori K, Donowitz M, Burton J (1984) Intact jejunal absorption of a synthetic nonapeptide renin inhibitor. Fed Proc 43 (943): 446Google Scholar
  142. Takaori K, Hartley LH, Burton J (1987) Hypotensive effects of the renin inhibitor (RI-78) and the converting enzyme inhibitor (teprotide) in conscious monkeys. Clin Exp Hypertens [A] 9: 387–390CrossRefGoogle Scholar
  143. TenBrink RE, Pals DT, Harris DW, Johnson GA (1988) Renin inhibitors containing Psi(CH20)pseudopeptide inserts. J Med Chem 31: 671–677Google Scholar
  144. Thaisrivongs S, Pals DT, Kati WM, Turner SR, Thomasco LM (1985) Difluorostatineand difluorostatone-containing peptides as potent and specific renin inhibitors. J Med Chem 28: 1553–1555PubMedCrossRefGoogle Scholar
  145. Thaisrivongs S, Pals DT, Harris DW, Kati WM, Turner SR (1986a) Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo. J Med Chem 29: 2088–2093PubMedCrossRefGoogle Scholar
  146. Thaisrivongs S, Pals DT, Kati WM, Turner SR, Thomasco LM, Watt W (1986b) Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues. J Med Chem 29: 2080–2087PubMedCrossRefGoogle Scholar
  147. Thaisrivongs S, Pals DT, Kroll DT, Turner SR, Han F-S (1987b) Renin inhibitors. Design of angiotensinogen transition-state analogues containing novel (2R, 3R, 4R, 5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid. J Med Chem 30: 976–982PubMedCrossRefGoogle Scholar
  148. Thaisrivongs S, Pals DT, Turner SR, Krol LT (1988) Conformationally constrained renin inhibitory peptides: ylactam-bridged isosteres as conformational restriction. J Med Chem 31: 1369–1376PubMedCrossRefGoogle Scholar
  149. Tree M, Atrash B, Donovan B, Gamble J, Hallett A, Hughes M, Jones DM, et al. (1983) New inhibitors of human renin tested in vitro and in vivo in the anaesthetized baboon. J Hypertens 1: 399–403PubMedCrossRefGoogle Scholar
  150. Tree M, Szelke M, Leckie B, Atrash B, Donovan B, Hallett A, Jones DM, et al. (1985) Renin inhibitors: their use in understanding the role of angiotensin II as a pressor hormone. J Cardiovasc Pharmacol [Suppl 4] 7: S49–S52CrossRefGoogle Scholar
  151. Umezawa H, Aoyagi T, Morishima M, Matsuzaki M, Hamada M, Takeuchi T (1970) Pepstatin, a new pepsin inhibitor produced by actinomycetes. J Antibiot (Tokyo) 23: 259–262Google Scholar
  152. Waeber B, Nussberger J, Brunner HR (1986) What have we learned about inhibitors of renin angiotensin system? Ann Endocrinol (Paris) 47: 167–177Google Scholar
  153. Webb DJ, Cumming AMM, Leckie BJ, Level AF, Morton JJ, Robertson JIS, Szelke M, Donovan B (1983) Reduction of blood pressure in man with H-142, a potent new renin inhibitor. Lancet 2: 1486–1487PubMedCrossRefGoogle Scholar
  154. Webb DJ, Manhem PJO, Ball SG, Inglis GI, Leckie BJ, Lever AF, Morton LJ, et al. (1985) A study of the renin inhibitor H142 in man. J Hypertens 3: 653–658PubMedCrossRefGoogle Scholar
  155. Webb DJ, Manhem PJO, Ball SG, Inglis GI, Leckie BJ, Lever AF, Morton LJ, et al. (1987) Clinical and biochemical effects of the renin inhibitor H142 in humans. J Cardiovasc Pharmacol [Suppl 7] 10: S69–S74CrossRefGoogle Scholar
  156. Wolfenden R (1976) Transition state analog inhibitors and enzyme catalysis. Annu Rev Biophys Bioeng 5: 271–306PubMedCrossRefGoogle Scholar
  157. Wood JM, Gulati N, Forgiarini P, Führer W, Hofbauer KG (1985) Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension 7: 797–803PubMedGoogle Scholar
  158. Wood JM, Heusser C, Gulati N, Forgiarini P, Hofbauer KG (1986) Monoclonal antibodies against human renin. Blood pressure effects in the marmoset. Hypertension 8: 600–605PubMedGoogle Scholar
  159. Wood JM, Baum H-P, Jobber RA, Neisius D (1987a) Sustained reduction in blood pressure during chronic administration of a renin inhibitor to normotensive marmosets. J Cardiovasc Pharmacol [Suppl 7] 10: S96–S98CrossRefGoogle Scholar
  160. Wood JM, Jobber RA, Baum H-P, Hofbauer KG (1987b) Comparison of chronic inhibition of renin and converting enzyme in the marmoset. Clin. Exp Hypertens [A] 9: 337–343CrossRefGoogle Scholar
  161. Wood JM, Stanton JL, Hofbauer KG (1987c) Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib 1: 169–185PubMedCrossRefGoogle Scholar
  162. Wood JM, Whitfield SL, Baum H-P, Jobber RA (1988) Effects of chronic administration of a renin inhibitor on renin-like activity in marmoset tissues (Abstr 1313). 12th Scientific Meeting of the International Society of Hypertension, May 22–26, KyotoGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • R. Henning
  • A. Wagner
  • B. A. Schölkens

There are no affiliations available

Personalised recommendations